PharmaVoice
THE FORUM FOR THE INDUSTRY EXECUTIVE

100 of the Most Inspiring People

Also featuring the RED JACKET AWARDS

www.pharmavoice.com
Inspiration and Innovation

Inspired leadership and innovative thinking are just two of the ways in which this year’s PharmaVOICE 100 can be described. Over the past dozen years we have showcased some of the most well-known names in the industry as well as the unsung heroes, each of whom are committed to making a difference in the lives of patients as well as their employees, colleagues, companies, and communities.

Each and every year, the inspirational stories of the PharmaVOICE 100, as well as our Red Jacket honorees, reaffirm what’s good about our industry. This diverse group of individuals is dedicated to moving the needle to improve all aspects of healthcare — from discovery to commercialization to delivery. They are imagining new possibilities and disrupting the status quo through new and enhanced business models with the patient at the center, creating innovative breakthroughs in science and clinical process improvements, developing new ways to communicate and engage, implementing enhanced talent development techniques, and much more. We hope you are inspired to innovate in your own unique way.

These dedicated company leaders, entrepreneurs, change agents, researchers and scientists, clinical experts, regulators, marketers and creative experts, patient advocates, mentors, and technologists are dedicated to innovation, transformation, and evolution. They represent every aspect of the healthcare ecosystem and are united by a common bond: to make a difference.

These 100 individuals as identified by you, our readers, are innovators creating new opportunities and identifying next steps in an effort to shape and evolve the life-sciences industry for sustainable success. They are envisioning new products and companies to address the needs of patients. And they are philanthropists, who are dedicated to paying it forward personally and through their companies.

In addition to the thoughtful profiles showcasing each individual, we have compiled several informative articles that capture these industry leaders’ insights on the topics of innovation and the challenges and opportunities they face as leaders. These articles can only be found online in our bonus content; please log onto pharmavoice.com to read more.

With thousands of nominations to consider, we rely on the personal accounts from you, our readers, that detail the inspirational and innovative nature of these individuals. Thanks to all of you who took time out of your schedules to nominate the individuals who are making a difference to you, our industry, patients’ lives, and the companies and organizations that make up our ecosystem. We also want to thank all of our PharmaVOICE 100 honorees and Red Jacket award winners for taking the time to share their personal stories with us. Please join us in extending warm congratulations to this esteemed group of individuals. And join us September 15 in New York to celebrate the accomplishments of our current and past honorees. For more information about this unique event, please go to www.pharmavoice.com/pharmavoice-100-celebration-schedule-of-events.

Taren Grom
Editor
**Getting to know...**

**John W. Hubbard, Ph.D.**

**TITLE:** President and CEO  
**COMPANY:** Bioclinica  
**EDUCATION:** Ph.D., Physiological Psychology and Physiology, University of Tennessee  
**FAMILY:** Wife of 36 years  
**HOBBIES:** Martial Arts, 3rd Degree Black Belt and senior instructor, international travel, home improvements, and gardening  
**BUCKET LIST:** Achieving his 4th Degree Black Belt — Master Level and continuing to travel around the world learning about different cultures  
**AWARDS/HONORS:** Fellow, American College of Clinical Pharmacology (1994); Accomplished Alumni Award, University of Tennessee (2009); Distinguished Alumnus Award, Department of Psychology, Commencement Speaker, University of Tennessee College of Arts & Sciences (2012); Fred J. Epstein M.D., Lifetime Achievement Award, 11th Annual Dream & Promise Awards Benefit, Children’s Brain Tumor Foundation (2013); University of Tennessee Alumni Professional Achievement Award (2014); Award in Appreciation for your Commitment to Pfizer Quality, (2014)  
**ASSOCIATIONS:** American College of Clinical Pharmacology; American Association for the Advancement of Science; American Society of Clinical Pharmacology and Therapeutics; Drug Information Association; Society of Sigma Xi

---

**Positive. Resilient.**

Dr. John Hubbard inspires others by leading by example and by empowering teams to achieve beyond what they think is possible.

“Despite years of trying, we still have an industry with multiple siloes — from research, through development and commercialization,” he says. “This challenge is now amplified due to extreme commercial pressures across the biopharmaceutical and healthcare ecosystem and the need to accelerate the development of more effective therapies.”

Under Dr. Hubbard’s stalwart leadership, Bioclinica has grown from its original two divisions to three business segments comprising a total of nine divisions. He expanded the company’s solution sets, once focused on eClinical and imaging, into adjacent areas through strategic acquisitions of leading providers in the areas of patient recruitment-retention, postapproval research, clinical site network, safety and regulatory, and financial lifecycle solutions.

In addition to his talent at delivering growth in alignment with industry needs, Dr. Hubbard is equally passionate about innovation and encourages every team member to pursue finding new ways to address the industry’s challenges each and every day.

---

**DR. JOHN HUBBARD**

**Breaking Down Barriers to Innovation**

Since taking the helm as Bioclinica’s president and CEO in January 2015, John Hubbard, Ph.D., has dramatically changed the company under his leadership and is bringing transformative solutions to the industry.

With extensive insight into the complexities inherent in the drug development process, Dr. Hubbard has created an agile organization committed to surfing — and realizing — new possibilities within R&D. To this end, his strategic vision centers on simplifying the drug development process, shortening cycle times, and rein in rising costs. He believes more needs to be done to break down the barriers across the industry and improve collaboration with patients, investigators, regulators, payers, service providers, and the industry.

Driven to innovate by curiosity

Dr. Hubbard has a history of breaking down the barriers to innovation.

While at Pfizer as senior VP and worldwide head of development operations, Dr. Hubbard directed and oversaw trial operations and management of more than 450 clinical projects a year and spearheaded initiatives to improve the efficiency and productivity in pharma R&D. He served on the executive taskforce that redesigned Pfizer’s R&D organization, which ultimately led to a significant improvement in quality and increase in productivity from 2010 to 2014. The challenges Pfizer faced were the need to reduce enterprise R&D costs by $2 billion, resolve a clinical warning letter, improve GCP data quality, transition from multiple functional service providers to two global CROs, and deliver the development portfolio on time and on budget.

“This was one of the most challenging positions and assignments I have ever had in my 30-year career,” he says. “I also found it extremely rewarding working with a great team to achieve these results.”

During Dr. Hubbard’s more than 11 years as group president of ICON’s global clinical research services business, the CRO’s largest business division, he achieved a consolidated annual growth rate of 25% to 35%, and revenue grew from $85 million in 1999 to just under $1 billion by the end of 2010.

Dr. Hubbard measures success by his influence on the industry, both through the people he has worked with and the results achieved to bring new innovative drugs to the market.

A trusted, well-liked, and respected leader, Dr. Hubbard leads by empowering team members to achieve beyond what they think is possible. Motivation, he believes, comes from enjoying what you do, but also from interactions with others.

“We sometimes forget the impact we have on people, both through the work we do to bring new drugs to market, but also in our daily interactions,” Dr. Hubbard says. “Progress is achieved, when people have the freedom to make mistakes and learn through the process. In the long-term, career achievements are about a mix of impact on industry and on people. I would like to be remembered as an innovator and calculated risk-taker who brought improvements to the clinical development process. I would also like to be remembered as a good leader and mentor.”
Who’s on the List — 2016

INDEX BY SECTION

COMMANDERS & CHIEFS
Julie Adrian ...................................................... Chandler Chico
Agency, inVentiv Health
Mary Anderson ............................................. Ogilvy CommonHealth
Medical Education and SCI Scientific
Communications & Information
Dr. Udit Batra ............................................. MilliporeSigma, the life
science business of Merck KGaA
Nancy Berg .................................................. International Society for
Pharmacoeconomics and Outcomes Research
Dr. Paul Bolino ........................................... WAVE Life Sciences
Mark Bouch ................................................... TrialCard
Louis Breton .............................................. Calimmune
Tim Davis .............................................. Exco InTouch
Dr. Donald Deieso ........................................ WIRB-Copernicus Group
Loiri Grant .................................................. Klick Health
Adele Gulfo .................................................. Mylan
Dr. Magali Haas ........................................... Cohen Veterans Bioscience
Steve Hamburg ........................................... Calcium
Debbie Hart .................................................. BioNJ
Dr. John Hubbard ........................................ BioClinica
Mike Kaufmann .......................................... Cardinal Health
Ken Keller .................................................. Daiichi Sankyo
Dr. Lawrence Kim ...................................... Moderna Therapeutics
Joe Kuchta .................................................. Sandbox
Brian Loew .................................................. Inspire
Juan Mantelle .............................................. ProSolus
Jennifer Matthews ...................................... The Bloc
Matt McNally ............................................ Publicis Health
Dr. Clive Meanwell ..................................... The Medicines Company
Dr. Jules Mitchel .......................................... Target Health
Carolyn Morgan .......................................... precisioneffect
Dr. Brian Nightengale ................................. Xcenda
Chris Perkins .............................................. Altasciences Clinical Research
Fred Petito .............................................. Guidemark Health
Jim Robinson ............................................ Astellas Pharma US
Julie Ross ................................................... Advanced Clinical
Shideh Sedgh Bina ...................................... Insigniam
Greg Skalicky ............................................. inVentiv Health
Lisa Stockman ............................................ Evoke Health
Heather Torak ........................................... CluePoints
Dr. Robert Urban ......................................... Johnson & Johnson
Clareece West ........................................... MedNet Solutions
Dr. Mike Wilkinson ...................................... PPD
Andy Woolf ............................................... Bionical
Alex Zapesochny ....................................... iCardiac Technologies

ENTREPRENEURS
Dr. Lisa Boyette ........................................... Curable
Kerrie Brady .............................................. Centrexion Therapeutics
Susan Cobian ........................................... HYC Health
Gregg Fisher .............................................. The Stem
Norm Goldfarb .......................................... MAGi
Dr. Kate Hersov ........................................... Medikidz
William King ............................................ Zephyr Health
Stephanie Lapierre ..................................... teabook
Stu Libby .................................................. Zipdrug
Dr. Jay Lichter ........................................... Avalon Ventures
Michael Maret ........................................... Confideo
Rishi Shah .................................................. ContextMedia

CHANGERS AGENTS
Gil Bashe .................................................. Finn Partners

RESEARCHERS & SCIENTISTS
Deirdre BeVard ........................................... Nektar Therapeutics
Brion Brandes ........................................... Spectra BioPharma Selling Solutions
Cindy Cetani .............................................. Novartis International
Jean Chitwood ........................................... INC Research
Dr. Marianne De Backer .............................. Johnson & Johnson
Amy Dowell ............................................. HCB Health
Brad Hardy .............................................. Kowa Pharmaceuticals America
Dr. Julian Jenkins ........................................ GlaxoSmithKline
Alison Little .............................................. KPMG
Phil Mann ............................................... MicroMass Communications
April Mulroy ........................................... Medidata Solutions
Dr. Bill Trombetta ...................................... Saint Joseph’s University
Kilian Weiss ........................................... Veeva Systems

CLINICAL EXPERTS
Sandra Chase ........................................... Continuum Clinical
Dr. Urvaka DeNoble ................................... PAREXEL
Amy Grahn ................................................ Horizon Pharma
Christina Hughes ....................................... Bracket
Lindy Jones ............................................... Quintiles
Craig Lipset ............................................... Pfizer
Dr. Chris Smyth .......................................... Novella Clinical
Dr. Philippe Szapary .................................... Janssen Research & Development

CREATIVES
Laurie Bartolomeo .................................... Dudnyk
Dr. Edward Nathan .................................... PulseCx
Jeff Perino ............................................... Triple Threat Communications

MARKETERS
Victoria Noble ........................................... Shire
Jason Noto .............................................. Sunovion Pharmaceuticals
Michelle Petroff ...................................... Fingerpaint

PATIENT ADVOCATES
Carolyn Dumond .................................... Myriad Genetic Laboratories
Kelli Duprey ............................................ Boehringer Ingelheim
Chemelle Evans ....................................... Snow Companies
Lise Hall .................................................. AstraZeneca
Nicole Hebert ................................. United BioSource Corporation (UBC)
Valerie Kobzjej ........................................... Celgene
Dr. Caroline Kurtz ..................................... Ironwood Pharmaceuticals

MENTORS
Brian Goff ............................................... Baxalta
Dr. Catherine Sohn ................................... Sohn Health Strategies
Dr. Stuart Sowder ...................................... Pfizer

TECHNOLOGISTS
Sam Anwar .............................................. eClinical Solutions
Elisa Cascade ........................................... DrugDev
Justin Freid .............................................. CMI/Compas